Importance: To make progress toward precision psychiatry, it is crucial to move beyond case-control studies and instead capture individual variations and interpret them in the context of a normal range of biological systems. Objective: To evaluate whether baseline deviations from a normative reference range in subcortical volumes are better predictors of antipsychotic treatment response than raw volumes in patients with first-episode psychosis (FEP) who were naive to antipsychotic medication. Design, Setting, and Participants: In this prospective longitudinal study, patients with first-episode psychosis who were referred from different clinical settings (emergency department, inpatient units, and outpatient clinics) at the University of Alabama at Birmingham were included. A total of 286 patients were screened, 114 consented, 104 enrolled in the treatment trial, and 85 completed the trial. Patients were observed for 16 weeks. Controls were matched by age and sex. Data were collected between June 2016 and July 2021, and data were analyzed from August 2021 to June 2022. Interventions: Risperidone on a flexible dosing scheme for 16 weeks. There was an option to switch to aripiprazole for excessive adverse effects. Main Outcomes and Measures: The main outcome of this study was to evaluate, in patients with FEP who were naive to antipsychotic medication, the association of baseline raw volumes and volume deviations in subcortical brain regions with response to antipsychotic medication. Raw brain volumes or volume deviation changes after treatment were not examined. Results: Of 190 included participants, 111 (58.4%) were male, and the mean (SD) age was 23.7 (5.5) years. Volumes and deviations were quantified in 98 patients with FEP, and data from 92 controls were used as comparison for case-control contrasts and reference curve calibration. In case-control contrasts, patients with FEP had lower raw thalamus (P = .002; F = 9.63; df = 1), hippocampus (P = .009; F = 17.23; df = 1), amygdala (P = .01; F = 6.55; df = 1), ventral diencephalon (P = .03; F = 4.84; df = 1), and brainstem volumes (P = .004; F = 8.39; df = 1). Of 98 patients, 36 patients with FEP (36%) displayed extreme deviations. Associations with treatment response significantly differed between raw volume and deviation measures in the caudate (z = -2.17; P = .03) and putamen (z = -2.15; P = .03). Conclusions and Relevance: These data suggest that normative modeling allows capture of interindividual heterogeneity of regional brain volumes in patients with FEP and characterize structural pathology in a clinically relevant fashion. This holds promise for progress in precision medicine in psychiatry, where group-level studies have failed to derive reliable maps of structural pathology.
Importance: To make progress toward precision psychiatry, it is crucial to move beyond case-control studies and instead capture individual variations and interpret them in the context of a normal range of biological systems. Objective: To evaluate whether baseline deviations from a normative reference range in subcortical volumes are better predictors of antipsychotic treatment response than raw volumes in patients with first-episode psychosis (FEP) who were naive to antipsychotic medication. Design, Setting, and Participants: In this prospective longitudinal study, patients with first-episode psychosis who were referred from different clinical settings (emergency department, inpatient units, and outpatient clinics) at the University of Alabama at Birmingham were included. A total of 286 patients were screened, 114 consented, 104 enrolled in the treatment trial, and 85 completed the trial. Patients were observed for 16 weeks. Controls were matched by age and sex. Data were collected between June 2016 and July 2021, and data were analyzed from August 2021 to June 2022. Interventions: Risperidone on a flexible dosing scheme for 16 weeks. There was an option to switch to aripiprazole for excessive adverse effects. Main Outcomes and Measures: The main outcome of this study was to evaluate, in patients with FEP who were naive to antipsychotic medication, the association of baseline raw volumes and volume deviations in subcortical brain regions with response to antipsychotic medication. Raw brain volumes or volume deviation changes after treatment were not examined. Results: Of 190 included participants, 111 (58.4%) were male, and the mean (SD) age was 23.7 (5.5) years. Volumes and deviations were quantified in 98 patients with FEP, and data from 92 controls were used as comparison for case-control contrasts and reference curve calibration. In case-control contrasts, patients with FEP had lower raw thalamus (P = .002; F = 9.63; df = 1), hippocampus (P = .009; F = 17.23; df = 1), amygdala (P = .01; F = 6.55; df = 1), ventral diencephalon (P = .03; F = 4.84; df = 1), and brainstem volumes (P = .004; F = 8.39; df = 1). Of 98 patients, 36 patients with FEP (36%) displayed extreme deviations. Associations with treatment response significantly differed between raw volume and deviation measures in the caudate (z = -2.17; P = .03) and putamen (z = -2.15; P = .03). Conclusions and Relevance: These data suggest that normative modeling allows capture of interindividual heterogeneity of regional brain volumes in patients with FEP and characterize structural pathology in a clinically relevant fashion. This holds promise for progress in precision medicine in psychiatry, where group-level studies have failed to derive reliable maps of structural pathology.
Authors: Fernando Caravaggio; Jun Ku Chung; Eric Plitman; Isabelle Boileau; Philip Gerretsen; Julia Kim; Yusuke Iwata; Raihaan Patel; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero Journal: Hum Brain Mapp Date: 2017-07-28 Impact factor: 5.038
Authors: Mariam Zabihi; Marianne Oldehinkel; Thomas Wolfers; Vincent Frouin; David Goyard; Eva Loth; Tony Charman; Julian Tillmann; Tobias Banaschewski; Guillaume Dumas; Rosemary Holt; Simon Baron-Cohen; Sarah Durston; Sven Bölte; Declan Murphy; Christine Ecker; Jan K Buitelaar; Christian F Beckmann; Andre F Marquand Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2018-12-19
Authors: Thomas Wolfers; Christian F Beckmann; Martine Hoogman; Jan K Buitelaar; Barbara Franke; Andre F Marquand Journal: Psychol Med Date: 2019-02-14 Impact factor: 7.723
Authors: Nina Vanessa Kraguljac; Thomas Anthony; Charity Johanna Morgan; Ripu Daman Jindal; Mark Steven Burger; Adrienne Carol Lahti Journal: Mol Psychiatry Date: 2020-05-12 Impact factor: 15.992
Authors: Meghann C Ryan; L Elliot Hong; Kathryn S Hatch; Si Gao; Shuo Chen; Krystl Haerian; Jingtao Wang; Eric L Goldwaser; Xiaoming Du; Bhim M Adhikari; Heather Bruce; Stephanie Hare; Mark D Kvarta; Neda Jahanshad; Thomas E Nichols; Paul M Thompson; Peter Kochunov Journal: Hum Brain Mapp Date: 2022-02-03 Impact factor: 5.399
Authors: Christian Beckmann; Andre F Marquand; Saige Rutherford; Charlotte Fraza; Richard Dinga; Seyed Mostafa Kia; Thomas Wolfers; Mariam Zabihi; Pierre Berthet; Amanda Worker; Serena Verdi; Derek Andrews; Laura Km Han; Johanna Mm Bayer; Paola Dazzan; Phillip McGuire; Roel T Mocking; Aart Schene; Chandra Sripada; Ivy F Tso; Elizabeth R Duval; Soo-Eun Chang; Brenda Wjh Penninx; Mary M Heitzeg; S Alexandra Burt; Luke W Hyde; David Amaral; Christine Wu Nordahl; Ole A Andreasssen; Lars T Westlye; Roland Zahn; Henricus G Ruhe Journal: Elife Date: 2022-02-01 Impact factor: 8.713